search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Randomised controlled trial of the treatment of warts in general practice.


- candidate number1720
- NTR NumberNTR419
- ISRCTNISRCTN42730629
- Date ISRCTN created27-jan-2006
- date ISRCTN requested18-nov-2005
- Date Registered NTR22-sep-2005
- Secondary IDsN/A 
- Public TitleRandomised controlled trial of the treatment of warts in general practice.
- Scientific TitleRandomised controlled trial of the treatment of warts in general practice.
- ACRONYMWARTS: WArts Randomized Treatment Study
- hypothesisThe usual treatment for warts in Dutch general practice is cryotherapy with liquid nitrogen. More than 50% of all warts are treated with cryotherapy alone and in only 14% salicylic acid is used as mono-therapy. The prestigious Cochrane review concludes that there is an urgent need for high-quality randomised controlled trials on the routine treatments for common warts, particularly cryotherapy. While there is convincing evidence for the efficacy of topical salicylic acid compared to placebo, high quality studies in which cryotherapy and salicylic acid compared to natural history are still lacking. According to the Cochrane review the most urgent need is for a trial to compare topical salicylic acid, cryotherapy and placebo. Since the most recent amendment (May 2003) no new studies are published.
- Healt Condition(s) or Problem(s) studiedWarts (Verruca vulgaris)
- Inclusion criteriaAll patients from the age of 4 onward, who present themselves to their practice with one or more new warts of the type vulgaris on hands or feet will be included? New warts are warts who are presented for the first time in the general practice by patients who have had no general practice (or dermatological) treatment for warts in the past year. For all patients duration of presence of the warts and the previous treatment(s) will be registered.
- Exclusion criteriaExclusion criteria are: immuno-incompetent patients and mosaic warts larger than 1 cm in diameter.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlNot applicable
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-mrt-2006
- planned closingdate1-mrt-2008
- Target number of participants250
- InterventionsTreatment arms For the treatment with cryotherapy we chose for a high-intensity regimen: a 2-weekly consultation till the wart has disappeared (until max. 13 weeks), 3 applications of the same wart per session, each application until a frozen halo appears of 2 mm around it?s base. For the local treatment with salicylic acid vaseline album (petrolatum) we use a once a day application of a concentration of 40% for warts on the sole of the feet and on other parts of the skin. We choose for a concentration of 40% to offer patients a stronger therapy than the over-the-counter therapies (like Formule-W), which have a concentration of 17%. Covering the skin up with tape will protect the skin around the wart. Application will be continued till the wart has disappeared (max. until 13 weeks). Patients who were randomised into the natural history arm will be informed about the high spontaneous cure rate. We refrained from a placebo-comparison because this insufficiently resembles daily practice. An expectantly awaiting group will in the intervention period will reliably reflect patient behaviours, including seeking of additional therapy (ability to maintain the expectantly awaiting policy).
- Primary outcomeThe primary outcome is defined as ‘cure', which means that the wart(s) have totally disappeared (normal skin) at 13 weeks.
- Secondary outcome1. The number of warts that still exists at follow-up, irrespective of the extent of regression (because for a separate wart regression can not be validly assessed.); 2. The subjective hindrance caused by the warts as scored by the patient on a numerical rating scale (0-10); 3. The subjective hindrance caused by the treatment as scored by the patient on a seven point scale (during the treatment period this will be scored weekly in a booklet); 4. Pain and other adverse effects of the treatments (pain, new warts, scars, irritation of the skin, dermatitis discomfort, invalidation, time); 5. Subjective judgement of the effect of the treatment by the patient at follow-up subjective judgement of the effect of the treatment by the research nurse at follow-up; 6. Referral to a dermatological department , assessed at 26 weeks After three months of the intervention period, patients for whom the warts have not disappeared are free to Switch therapy. In the follow-up period we will carefully register to which therapies patients have switched and also if, and after how long this therapy leads to total disappearance of the warts; 7. The consumption of co-interventions during the intervention period and thereafter will also be used as secondary endpoints.
- Timepoints
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. J.A.H. Eekhof
- CONTACT for SCIENTIFIC QUERIESDr. J.A.H. Eekhof
- Sponsor/Initiator
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development
- PublicationsN/A
- Brief summary* objective(s) / research question(s): Is treatment with cryotherapy more effective than treatment with salicylic acid and are both therapies more effective than an expectant awaiting policy (natural history)? Are there subgroups (age, location, number of warts, previous self-treatment), which react differently on therapy? * study design: Randomised controlled trial in 32 GP practices * study population(s)/ datasets: Patients (all ages) contacting the general practice with warts. * intervention: Comparison of cryotherapy (2-week interval), salicylic acid therapy and an expectantly awaiting policy. * outcome measures: 1) Cure rate (total disappearance observed by a blinded research nurse), 2) number of persisting warts, subjective hindrance caused by warts and acceptability of therapy as scored by the patient, 3) adverse effects (including new warts) of the three approaches, 4) additional treatment during and after intervention period (13 weeks). Follow-up moments at 4, 13 and 26 weeks * power/data analysis: Because of presumed less adverse effects and logistic and practical advantages salicylic acid is the preferential therapy when the cure rate for cryotherapy is not more than 20% higher than salicylic acid. . With an alpha of 0.05 and a beta of 0.20 we need 71 patients in each group. When we estimate a loss to follow-up of 20% we need about 250 patients with new warts. With this number we can also detect a difference of 20% between expectantly the awaiting policy and the active treatments. * time schedule: Months 1-6: development patient record form, recruitment of general practitioners and practice assistants and instruction in uniform application of cryotherapy, instruction for ointment treatment. Instruction of research nurses on protocol and on assessment of warts. Months 6-18: patient inclusion, intervention, data collection. Months 18-24: data analysis and preparation of scientific reports.
- Main changes (audit trail)
- RECORD22-sep-2005 - 7-mrt-2006


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl